• S2 Episode 2: How Bladder Cancer Immunostimulant N-803 May Shake Things Up

  • Apr 20 2023
  • Length: 20 mins
  • Podcast

S2 Episode 2: How Bladder Cancer Immunostimulant N-803 May Shake Things Up

Listen for free

View show details

  • Summary

  • Drs Cheryl Lee and Karim Chamie talk about efforts to develop nogapendekin alfa, aka N-803, and where it may fit into the shifting treatment paradigm for non-muscle invasive bladder cancer.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987105). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    BCG-Unresponsive High-Grade Non-Muscle-Invasive Bladder Cancer: What Does the Practicing Urologist Need to Know? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997797/

    Final Clinical Results of Pivotal Trial of IL-15rαfc Superagonist N-803 With BCG in BCG-Unresponsive CIS and Papillary Non-Muscle-Invasive Bladder Cancer (NMIBC) https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4508

    PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14) https://www.clincosm.com/trial/pk-sub-quilt-3032-ca-alt-803-01-16-2005-14
    Show more Show less
Show more Show less

What listeners say about S2 Episode 2: How Bladder Cancer Immunostimulant N-803 May Shake Things Up

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available